GlassScriptPhysician profile
Brian John Leberthon
NPI 1326023979
$37,024.96
in general payments reported to CMS, 2019-2025
89 companies · $6,218 in 2025
The $6,218 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,277 · 2020: $3,717 · 2021: $4,876 · 2022: $5,706 · 2023: $6,221 · 2024: $6,011 · 2025: $6,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $759 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,314.92 |
| Education | $758.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.34 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,395.24 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $2,704.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,205.98 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $2,203.16 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $1,676.84 | 2019-2025 | Erleada, Darzalex, Talvey |
| Celgene Corporation | $1,601.57 | 2019-2025 | Pomalyst, Reblozyl, Pomalyst |
| Amgen INC. | $1,522.67 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $1,436.47 | 2019-2025 | |
| Genzyme Corporation | $1,319.79 | 2019-2025 | |
| Puma Biotechnology, INC. | $1,289.81 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,118.73 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $1,094.89 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $1,062.76 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Gilead Sciences, INC. | $951.49 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $747.10 | 2019-2024 | Venclexta, Tecentriq, Alecensa |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $656.02 | 2020-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $597.97 | 2019-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $552.04 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Seagen INC. | $530.34 | 2020-2025 | Adcetris, Padcev, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $519.56 | 2019-2024 | Iclusig, Ninlaro, Fruzaqla |
| Jazz Pharmaceuticals INC. | $491.61 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $463.59 | 2019-2025 | |
| Lilly USA, LLC | $463.11 | 2019-2025 | Jaypirca, Verzenio |
| Foundation Medicine, INC. | $410.03 | 2019-2023 | |
| Acrotech Biopharma INC. | $385.07 | 2021-2024 | Beleodaq |
| Emd Serono, INC. | $362.79 | 2019-2025 | Bavencio |
| Abbvie INC. | $331.47 | 2019-2025 | |
| Pharmaessentia USA Corporation | $313.09 | 2022-2025 | Besremi |
| Tersera Therapeutics LLC | $286.71 | 2020-2025 | Zoladex |
| Array Biopharma INC | $268.78 | 2020-2025 | Mektovi, Braftovi, Tukysa |
| Taiho Oncology, INC. | $267.91 | 2019-2024 | |
| Astellas Pharma US INC | $256.96 | 2019-2025 | Vyloy, Padcev |
| Eisai INC. | $228.86 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $228.10 | 2022-2025 | Fotivda |
| Spectrum Pharmaceuticals INC. | $219.33 | 2024-2025 | Rolvedon |
| Agios Pharmaceuticals, INC. | $208.47 | 2020-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $184.21 | 2019-2025 | Orserdu, Elzonris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.41 | 2019-2025 | Gilotrif |
| Dendreon Pharmaceuticals LLC | $177.59 | 2019-2025 | Provenge |
| Coherus Oncology, INC. | $169.87 | 2023-2025 | Loqtorzi |
| Exelixis INC. | $150.51 | 2019-2022 | |
| Sobi, INC | $136.82 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $134.28 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $109.81 | 2020-2025 | Libtayo |
| Beigene USA, INC. | $105.66 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $103.22 | 2021-2025 | Somatuline Depot, Onivyde |
| Janssen Scientific Affairs, LLC | $102.18 | 2022 | |
| Novocure INC. | $101.38 | 2021-2025 | Optune, Optune Gio |
| Mirati Therapeutics, INC. | $98.54 | 2023-2024 | Krazati |
| Immunocore Limited | $97.31 | 2023 | Kimmtrak |
| Verastem, INC. | $91.08 | 2019 | |
| Sumitomo Pharma America, INC. | $88.25 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $85.07 | 2023-2025 | Epkinly |
| Kyowa Kirin, INC. | $83.50 | 2019-2025 | Poteligeo |
| Partner Therapeutics, INC. | $82.10 | 2019-2020 | |
| Tesaro, INC. | $76.86 | 2019 | |
| Azurity Pharmaceuticals, INC. | $76.64 | 2025 | Danziten |
| Myovant Sciences INC. | $74.91 | 2021-2022 | |
| Immunogen, INC. | $69.75 | 2023-2024 | Elahere, Elahere |
| Clovis Oncology, INC. | $68.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $67.45 | 2019-2024 | Xarelto |
| Eusa Pharma (US) LLC | $65.62 | 2020-2022 | |
| Secura Bio, INC. | $64.62 | 2020 | |
| Epizyme, INC. | $63.54 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $58.73 | 2021-2023 | Onpattro |
| Legend Biotech USA INC. | $56.80 | 2024-2025 | Carvykti |
| Ge Healthcare | $50.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $50.00 | 2024 | Jynarque |
| Kite Pharma, INC. | $46.85 | 2021-2023 | |
| Syndax Pharmaceuticals, INC. | $44.81 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $43.62 | 2019 | |
| Dova Pharmaceuticals | $40.05 | 2020-2021 | |
| Mylan Institutional INC. | $38.73 | 2020-2022 | |
| Deciphera Pharmaceuticals INC. | $36.39 | 2021 | |
| Boston Scientific Corporation | $27.78 | 2025 | General - Pain Management |
| Adc Therapeutics America, INC. | $23.64 | 2023 | |
| Adaptive Biotechnologies Corporation | $23.05 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.05 | 2024 | Cosela |
| Sanofi-Aventis U.S. LLC | $20.52 | 2020 | |
| Global Blood Therapeutics, INC. | $20.31 | 2022 | |
| Accord Healthcare, INC. | $20.22 | 2025 | |
| West Therapeutics Development, LLC | $20.14 | 2020 | |
| Caris Mpi, INC. | $19.76 | 2025 | Mi Cancer Seek |
| Helsinn Therapeutics (U.S.), INC. | $19.65 | 2019 | |
| Morphosys, US INC. | $17.81 | 2023 | Monjuvi |
| Aurobindo Pharma USA, INC. | $13.86 | 2020 | |
| Menarini Silicon Biosystems, INC. | $13.50 | 2024 | |
| Immunomedics, INC. | $11.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Leberthon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.